It’s been three years since the FDA approved PrEP (Pre-Exposure Prophylaxis) for use by HIV-negative individuals to prevent them from being infected with HIV. When PrEP as treatment was first introduced, there was a great deal of excitement in the provider community, particularly among those of us who specialize in treating people with HIV and those at higher risk of contracting it. In its original clinical trials PrEP showed remarkable efficacy as a prevention tool.
Earlier this fall researchers at Kaiser Permanente Medical Center in San Francisco released what I Read more...